Data from the IMPRESS study 2,3
AIM: To compare resource use in the 6 and 12 months before and after rifaximin- α initiation in UK patients with HE.
This study was sponsored by Norgine.
- 4% patients (9/145) reported adverse drug reactions(ADRs)
- 4/9 of these patients had C difficile infection and none discontinued treatment
- No serious ADRs were reported